Core Insights - Evaxion A/S, a clinical-stage TechBio company, has developed novel vaccine design concepts for polio in collaboration with the Gates Foundation, utilizing its AI-Immunology™ platform [1][7] - The new polio vaccine concepts aim to combine the strengths of existing vaccines, addressing their shortcomings and enhancing the potential for polio eradication [2][3] - Evaxion will present these concepts at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026 [1][6] Vaccine Development - Current polio vaccines are based on inactivated or attenuated virus versions, which have limitations in certain settings [2] - The AI-Immunology™ platform has enabled the development of hybrid capsid designs and de novo B-cell antigen approaches for the new polio vaccine [7][8] - Initial results from the new vaccine concepts support further development and potential collaboration opportunities [4] Additional Programs - Evaxion will also present data from its EVX-V1 program targeting Cytomegalovirus (CMV), which combines novel AI-discovered antigens with optimized versions of established CMV vaccine antigens [5][7] - The multi-targeted strategy of EVX-V1 is expected to enhance the protective potential of the future vaccine [5] Presentation Details - The presentation on the novel poliovirus vaccine will take place on April 1, 2026, at 16:40 ET, and will be led by Thomas Trolle, PhD [6] - An abstract on AI-powered target discovery for the CMV vaccine will be presented on April 2, 2026, at 10:25 ET by Pär Comstedt [6]

Core Insights - Vaxart, Inc. announced positive clinical results for its oral norovirus vaccine candidate, demonstrating safety and immunogenicity in lactating women, with passive antibody transfer to infants via breast milk [1][2] - The company reported a significant increase in revenue for 2025, totaling $237.3 million, compared to $28.7 million in 2024, primarily due to government contracts and a collaboration with Dynavax [12][18] - Vaxart has a cash position of $63.8 million as of December 31, 2025, providing a runway into the second quarter of 2027 [1][12] COVID-19 Vaccine Developments - The COVID-19 program reached a strategic inflection point with a collaboration with Dynavax, which is expected to provide funding and enhance the recognition of Vaxart's mucosal vaccine platform [2] - The company completed enrollment of approximately 5,400 participants for its Phase 2b trial, with safety data from the sentinel cohort expected in early Q2 2026 and full trial data anticipated in Q4 2026 [5][2] Norovirus Vaccine Developments - Vaxart's oral bivalent norovirus vaccine demonstrated a significant increase in norovirus-specific antibodies in lactating women, providing clinical evidence of passive mucosal immunity to infants [5][2] - The company plans to initiate its next norovirus clinical trial in 2026, pending partnership or funding [6] Financial Results - For the full year 2025, Vaxart reported a net income of $16.3 million, a significant turnaround from a net loss of $66.9 million in 2024 [12][18] - Research and development expenses increased to $201.6 million in 2025 from $74.2 million in 2024, primarily due to clinical trial expenses for the COVID-19 vaccine [12][18] - General and administrative expenses decreased to $17.6 million in 2025 from $20.8 million in 2024, attributed to lower personnel costs and legal fees [12][18]

Core Insights - Evaxion A/S experienced a transformational year in 2025, achieving significant milestones that strengthened its strategic, scientific, and financial position [2][30] - The company has cash reserves to fund operations into the second half of 2027, allowing for continued development of its AI-Immunology™ platform and R&D pipeline [2][27] Business Highlights - Key achievements in 2025 include the historic licensing of the infectious disease vaccine candidate EVX-B3 to MSD, which provides potential future revenue of up to $592 million [9][31] - The company replenished its R&D pipeline with new candidates, including EVX-04 for acute myeloid leukemia and EVX-B4 targeting Group A Streptococcus [9][10] - Evaxion received the Galien Foundation Prix Bridges Award for advancements in medical technology and AI, reinforcing its leadership in AI-based target discovery [9][19] R&D Update - The personalized cancer vaccine EVX-01 showed a 75% objective response rate in advanced melanoma patients, with 92% of patients still responding at two years follow-up [16][18] - EVX-04, developed using AI-Immunology™, demonstrated the ability to elicit specific immune responses and prevent tumor growth in preclinical models [22] - The company is also advancing its EVX-V1 program targeting Cytomegalovirus, with promising data on novel antigens [23][24] Financial Overview - Evaxion reported a net loss of $7.7 million for 2025, an improvement of $2.9 million compared to 2024, attributed to higher revenue and lower operating expenses [30] - Revenue for 2025 was $7.5 million, primarily from the MSD option exercise and a grant from the Gates Foundation [31] - Cash and cash equivalents increased to $23.2 million by the end of 2025, significantly up from $6.0 million in 2024, bolstered by capital market activities [34] Future Milestones - For 2026, Evaxion plans to launch a new application for autoimmune diseases using AI-Immunology™ and prepare for a phase 1 trial of EVX-04 [5][13] - The company aims to present additional biomarker and immunogenicity data for EVX-01 and complete regulatory filings for EVX-04 by the second half of 2026 [8][10]

Core Viewpoint - Karolinska Development AB's portfolio company SVF Vaccines has entered into a reverse acquisition agreement with Novakand Pharma, valued at approximately SEK 55 million, pending various approvals [1][3]. Group 1: Transaction Details - The reverse acquisition agreement allows Novakand to acquire all shares in SVF Vaccines, with payment made in newly issued shares of Novakand [1]. - SVF Vaccines shareholders will hold 66.7% of the combined company, while Novakand shareholders will hold 33.3% [3]. - The transaction is expected to be completed in the first quarter of 2026, subject to approval from an extraordinary general meeting of Novakand and regulatory authorities [1][3]. Group 2: Company Focus and Financials - Post-transaction, the combined company will concentrate on developing innovative vaccine therapies based on SVF's technology, while retaining Novakand's existing fractalkine program [4]. - The combined entity is projected to have sufficient working capital for the next 12 months, with plans for a capital raise to fund a Phase 1 study for the vaccine candidate SVF-001, estimated to cost SEK 30 million [4]. Group 3: Strategic Importance - The CEO of Karolinska Development emphasized that the stock market listing could accelerate SVF Vaccines' vaccine development, highlighting the company's commitment to supporting the capital raising process for the upcoming Phase 1 study [5]. - Karolinska Development holds a 33% ownership stake in SVF Vaccines, indicating a significant interest in the success of the combined entity [5].

Core Viewpoint - Vaxcyte Inc. (NASDAQ:PCVX) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by positive analyst ratings and upcoming clinical trials [1][4]. Group 1: Analyst Ratings and Price Targets - BTIG analyst Thomas Shrader has reiterated a Buy rating for Vaxcyte Inc. with a target price of $85, indicating an upside of over 83% from current levels [1]. - Consensus ratings show all 7 analysts have assigned Buy ratings, with a median 1-year price target of $100.80 per share, representing a potential upside of 117.2% [4]. Group 2: Clinical Trials and Product Development - Positive results from Phase 2 trials for the VAX-31 vaccine are expected to support the critical Phase 3 trials, which have a robust design and stringent success criteria [2]. - The target market for VAX-31 includes individuals aged 50 to 65, suggesting strong potential for market adoption [3]. - Vaxcyte Inc. focuses on developing next-generation vaccines using innovative synthetic methods and advanced chemistry to enhance immunological benefits [5].

Core Insights - Evaxion A/S has announced promising new data for its AML vaccine candidate, EVX-04, which shows strong T-cell responses and effective tumor growth prevention in preclinical models [1][5][10] - The data was presented at the American Society of Hematology Annual Meeting, highlighting the company's engagement with the scientific community and potential business partners [2] - The AI-Immunology™ platform has been instrumental in identifying novel ERV tumor antigens, which are targeted by EVX-04, showcasing the platform's unique capabilities in cancer vaccine development [3][4][11] Company Overview - Evaxion A/S is a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines, with a commitment to transforming patient care through innovative immunotherapies [12] - The company’s proprietary AI platform enables the identification of therapeutically relevant tumor antigens, which are crucial for the development of effective cancer vaccines [11][12] Product Details - EVX-04 is designed as an off-the-shelf therapeutic cancer vaccine specifically for acute myeloid leukemia (AML), addressing a significant unmet medical need due to the high mortality rates associated with the disease [10] - The vaccine targets non-conventional ERV tumor antigens, which are selectively expressed in tumors but absent in normal tissues, making them ideal candidates for cancer immunotherapy [4][10] AML Context - Acute myeloid leukemia (AML) is characterized by high mortality rates and limited treatment options, with a median age of diagnosis at 68 years [8][9] - Approximately 50% of AML patients are not fit for intensive treatment, leading to a low overall survival rate of 25% over three years for those receiving standard low-intensity chemotherapy [9]

Core Insights - Vaxart has entered into an exclusive license agreement with Dynavax for its COVID-19 oral pill vaccine candidate, potentially generating up to $700 million in cumulative proceeds plus royalties [1][4][3] - The company has completed enrollment of approximately 5,400 participants in its COVID-19 Phase 2b trial, with topline data expected in late 2026 and data from a 400-person sentinel cohort anticipated in the first quarter of 2026 [1][9] - Vaxart reported positive data from its Phase 1 clinical trial for its second-generation oral norovirus vaccine, indicating improved protection against infection [1][3] COVID-19 Vaccine Developments - The exclusive agreement with Dynavax includes a $25 million upfront license fee and a $5 million equity investment, with additional potential payments of $50 million and up to $195 million in regulatory milestone payments [4] - Vaxart retains operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase 2b clinical trial [4] - The company has received $125.9 million in cash payments associated with its COVID-19 vaccine program as of September 30, 2025 [9] Norovirus Vaccine Developments - Vaxart's second-generation oral pill norovirus vaccine constructs have shown significantly stronger antibody responses compared to first-generation constructs [3][9] - The company plans to publish complete results of the Phase 1 study in a peer-reviewed journal and is exploring partnership opportunities for its norovirus candidate [3][9] Financial Results for Q3 2025 - Vaxart reported revenue of $72.4 million for Q3 2025, a significant increase from $4.9 million in Q3 2024, primarily from government contracts [9][15] - Research and development expenses rose to $75.9 million in Q3 2025 from $15.1 million in Q3 2024, mainly due to increased clinical trial expenses [9][15] - The net loss for Q3 2025 was $8.1 million, an improvement from a net loss of $14.1 million in Q3 2024, with a net loss per share of $0.04 compared to $0.06 [9][15] Cash Position and Runway - As of September 30, 2025, Vaxart had cash, cash equivalents, and investments totaling $28.8 million, with a current runway extended into the second quarter of 2027 following the Dynavax agreement [1][9]

Core Points - Vaxart, Inc. will host a conference call to discuss its third quarter 2025 financial results on November 13, 2025, at 4:30 p.m. ET [2] - A stockholder fireside chat is scheduled for November 18, 2025, at 4:30 p.m. ET, where senior management will address frequently asked questions from stockholders [3] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform that allows for non-refrigerated storage and eliminates needle-stick injury risks [5] - The company's vaccine development programs include oral vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [5] - Vaxart has filed extensive domestic and international patent applications for its oral vaccination technology, which utilizes adenovirus and TLR3 agonists [5]

Core Insights - Evaxion A/S has made significant advancements in its AI-Immunology™ powered vaccine development, particularly in cancer and infectious diseases, showcasing strong data from its lead asset, EVX-01, and successfully out-licensing EVX-B3 to MSD [2][8][20] Business Highlights - The company has validated its technology and strategy through impressive data from EVX-01, which targets multiple neoantigens in cancer vaccines, and the out-licensing of EVX-B3 confirms its capabilities in infectious disease vaccines [2][8] - Evaxion's cash runway has been extended to the second half of 2027, bolstered by a $7.5 million payment from MSD and $7.2 million raised from capital market activities [8][25] - The appointment of Dr. Helen Tayton-Martin as the new CEO is expected to bring over 30 years of experience in biotech M&A and business development [8] Research & Development Update - The phase 2 trial of EVX-01 in advanced melanoma patients showed an Objective Response Rate (ORR) of 75%, with 12 out of 16 patients responding clinically, and 92% of patients still responding at the two-year follow-up [6][10] - Evaxion has expanded its pipeline with EVX-04, targeting non-conventional ERV tumor antigens for acute myeloid leukemia (AML), developed using the AI-Immunology™ platform [12][15] - The company has developed an automated vaccine design module to enhance the efficiency and quality of vaccine development, reducing design time from months to days [17][18] Financial Performance - For Q3 2025, Evaxion reported a net income of $4.6 million, a significant improvement from a net loss of $1.9 million in Q3 2024, driven by revenue from MSD's option exercise [27][28] - Revenue for the quarter was $7.5 million, primarily from the MSD option exercise and included contributions from the Gates Foundation [28] - Research and development expenses were $3.1 million for Q3 2025, compared to $2.6 million in the same period last year, while general and administrative expenses decreased to $1.4 million from $2.1 million [29][30] Equity and Cash Position - As of September 30, 2025, cash and cash equivalents were $10.6 million, up from $6.0 million at the end of 2024, with total equity improving to $16.6 million from a negative equity of $(1.7) million [32][34] - The company has successfully managed its financial strategy, resulting in improved equity and extended cash runway, with an operational cash burn expected to be approximately $14 million in 2025 [34]

Core Insights - Evaxion A/S is set to provide a business update and report its Q3 2025 financial results on October 31, 2025, before the Nasdaq CM opens [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in AI-Immunology™ powered vaccines, focusing on developing novel immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S is a pioneering TechBio company utilizing its AI platform, AI-Immunology™, to decode the human immune system [4] - The company has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]